# US 2018/0022736 A1 · Carboxylic acid compound, method for preparation thereof, and use thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2018/0022736 A1 - Document ID: US20180022736A1 - Status: Published application - Kind: A1 - Application number: 15/723,785 - Filed: 2017-10-03 - Published: 2018-01-25 - Earliest claimed: 2014-08-13 - Assignees: InventisBio Shanghai Ltd. - Applicants: Inventisbio Shanghai Ltd. - Inventors: Yueheng Jiang - Web page: https://patentgrep.com/patent/US20180022736A1 ## CPC - C07D 405/10: linked by a carbon chain containing aromatic rings - A61K 31/277: having a ring, e.g. verapamil - A61K 31/4418: having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine - A61K 31/4725: containing further heterocyclic rings - A61P 5/18: of the parathyroid hormones - A61P 5/20: for decreasing, blocking or antagonising the activity of PTH - A61P 9/00: Drugs for disorders of the cardiovascular system - A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis - A61P 9/12: Antihypertensives - A61P 13/04: for urolithiasis - A61P 13/12: of the kidneys - A61P 17/06: Antipsoriatics - A61P 19/02: for joint disorders, e.g. arthritis, arthrosis - A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents - A61P 35/00: Antineoplastic agents - A61P 39/02: Antidotes - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - C07B 59/002: {Heterocyclic compounds} - C07C 319/20: by reactions not involving the formation of sulfide groups - C07C 323/62: having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton - C07C 323/63: the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups - C07D 213/57: Nitriles - C07D 213/68: attached in position 4 - C07D 213/70: Sulfur atoms - C07D 213/74: Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals - C07D 401/04: directly linked by a ring-member-to-ring-member bond - C07B 2200/05: Isotopically modified compounds, e.g. labelled - C07C 2601/02: with a three-membered ring - C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F) - C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS ## Abstract The present invention relates to the technical field of medicine, and specifically relates to the carboxylic acid compound represented by the chemical formula I or chemical formula II, and a pharmaceutically acceptable salt, a prodrug, and a solvate thereof, and a method for preparation thereof, as well as a pharmaceutical composition containing the described substances, and a use thereof. ## Claims ### Claim at position 1 1-16. (canceled) ### Claim 17 A compound selected from the group consisting of or a pharmaceutically acceptable salt thereof. ### Claim 18 (depends on 17) The compound of claim 17, which is or a pharmaceutically acceptable salt thereof. ### Claim 19 (depends on 17) The compound of claim 17, which is or a pharmaceutically acceptable salt thereof. ### Claim 20 (depends on 17) The compound of claim 17, which is or a pharmaceutically acceptable salt thereof. ### Claim 21 (depends on 17) The compound of claim 17, which is or a pharmaceutically acceptable salt thereof. ### Claim 22 (depends on 17) The compound of claim 17, which is or a pharmaceutically acceptable salt thereof. ### Claim 23 (depends on 17) The compound of claim 17, which is or a pharmaceutically acceptable salt thereof. ### Claim 24 (depends on 17) The compound of claim 17, which is or a pharmaceutically acceptable salt thereof. ### Claim 25 (depends on 17) The compound of claim 17, which is or a pharmaceutically acceptable salt thereof. ### Claim 26 (depends on 17) The compound of claim 17, which is or a pharmaceutically acceptable salt thereof. ### Claim 27 (depends on 17) A pharmaceutical composition comprising the carboxylic acid compound according to claim 17, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. ### Claim 28 A method of treating gout in a human, comprising administering to the human an effective amount of a compound selected from the group consisting of or a pharmaceutically acceptable salt thereof. ### Claim 29 (depends on 28) The method of claim 28, comprising administering to the human an effective amount of compound or a pharmaceutically acceptable salt thereof. ### Claim 30 (depends on 28) The method of claim 28, comprising administering to the human an effective amount of compound or a pharmaceutically acceptable salt thereof. ### Claim 31 (depends on 28) The method of claim 28, comprising administering to the human an effective amount of compound or a pharmaceutically acceptable salt thereof. ### Claim 32 (depends on 28) The method of claim 28, comprising administering to the human an effective amount of compound or a pharmaceutically acceptable salt thereof. ### Claim 33 (depends on 28) The method of claim 28, comprising administering to the human an effective amount of compound or a pharmaceutically acceptable salt thereof. ### Claim 34 (depends on 28) The method of claim 28, comprising administering to the human an effective amount of compound or a pharmaceutically acceptable salt thereof. ### Claim 35 (depends on 28) The method of claim 28, comprising administering to the human an effective amount of compound or a pharmaceutically acceptable salt thereof. ### Claim 36 (depends on 28) The method of claim 28, comprising administering to the human an effective amount of compound or a pharmaceutically acceptable salt thereof. ### Claim 37 (depends on 28) The method of claim 28, comprising administering to the human an effective amount of compound or a pharmaceutically acceptable salt thereof. ### Claim 38 A method of reducing the blood uric acid level in a human, comprising administering to the human an effective amount of a compound selected from the group consisting of or a pharmaceutically acceptable salt thereof. ### Claim 39 A method of treating hyperuricemia in a human, comprising administering to the human an effective amount of a compound selected from the group consisting of or a pharmaceutically acceptable salt thereof.